 |
 |
||||||
Volume
5, March 2011 |
 |
||||||
 |
MaxCyte’s proprietary Flow Electroporation technology leads the way in high performance, high throughput transfection enabling the widest array of cost and time effective drug discovery assays. MaxCyte technology lets you get ahead by transfecting any molecule of interest, into any cell, at any scale. The goal of the MaxCyte Minute is to provide researchers like you with key application and scientific advancements to help you stay ahead in the world of drug discovery. |
||||||
IN THIS ISSUE
|
Rapid GPCR Screening
Eliminate the Need for Stable Cell Line Construction |
||||||
|
Upcoming
Events
ELRIG March 15, 2011 Cambridge, UK 2011 Targets & Tools Conference March 21-24, 2011 Berlin, Germany 17th Annual SBS March 27-31, 2011 Orlando, Florida Frequently Asked Questions
Can you freeze cells after transfection with MaxCyte STX?  |
In contrast, transient transfection, and more specifically MaxCyte STX flow electroporation, quickly and reproducibly transfects cells with minimal off target effects and proven performance in downstream GPCR assays such as cAMP regulation and calcium flux assays. Commonly used cell lines, such as CHO and HEK, as well as primary cells can be transfected in bulk with GPCR expression constructs alone or in combination with reporter or accessory plasmids. Up to 1 x1010 cells can be transfected at one time in less than thirty minutes. MaxCyte transient transfection streamlines GPCR screening and can reduce assay development time from months to days. Read more on increasing GPCR screening productivity and assay biorelevance: • Large-scale, Bulk Transfection for Simplified GPCR Screening • Primary Cell Transfection |
||||||
|
Flow Electroporation Capabilities and Case Studies:Rapid GPCR Screening and Functional Ion Channel Assays
MaxCyte's proprietary flow electroporation technology has been successfully applied in ex vivo cell
therapy and drug discovery pipelines where reproducibility, efficiency and the need for increased
cell numbers are critical. This technical paper discusses the merits of transient transfection
using flow electroporation versus other recombinant expression approaches and its application in
hit identification and lead optimization programs. Data are presented demonstrating the key
features of the MaxCyte® STX™ Scalable Transfection System, including broad applicability,
scalability, and the production of functionally relevant cells that enable its streamlined
integration within cell-based assay methodologies. Case studies are presented for large-scale
cellular GPCR screening and the functional characterization of multi-subunit voltage-gated ion
channels.
Download
|
||||||
March 15, 2011, Hinxton Hall, Cambridge, UK
March 21 – 24, 2011, Berlin, Germany
Learn more about how MaxCyte transfection can improve your Cell-based Ion Channel Screening!
MaxCyte will be presenting at DDTT's pre-conference workshop, Monday 21 March 2011 entitled,
Automated Electrophysiology in Drug Discovery.
March 27 – 31, 2011, Orlando, Florida
|
|||||||
Rather than using cells immediately after transfection, most cell types can be aliquoted and cryopreserved for use in future assays. MaxCyte scientists have developed several cryopreservation protocols that enable cell archiving with minimal impact on transgene expression or viability relative to non-cryopreserved cells. The images to the right represent U2OS cells electroporated using the MaxCyte STX and cryopreserved either 20 minutes or 4 hours post electroporation (EP). Cryopreserved cells were analyzed for viability and transgene expression 24 hours after thawing and compared with non-cryopreserved cells 24 hours post EP. |
|||||||
|
||||
